Literature DB >> 32758904

N-acetycysteine: A potential therapeutic agent in COVID-19 infection.

N Jaiswal1, M Bhatnagar2, H Shah3.   

Abstract

COVID-19 is an overwhelming pandemic which has shattered the whole world. Lung injury being the main clinical manifestation, it is likely to cause COPD (chronic obstructive pulmonary disease) and ARDS (acute respiratory distress syndrome). The possible cause behind this might be redox imbalance due to viral infection. Elevation in Glutathione (GSH) levels by administration of its promolecule might be effective. N-acetylcysteine is one such drug with potency to scavenge Reactive Oxygen Species, least side effects, and an effective precursor of glutathione. Consequently we hypothesize that N-acetylcysteine along with the conventional treatment may be treated as a potential therapeutic solution in cases of COVID-19 patients.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  COVID-19; Glutathione; N-acetylcysteine; Oxidative stress

Mesh:

Substances:

Year:  2020        PMID: 32758904      PMCID: PMC7380211          DOI: 10.1016/j.mehy.2020.110133

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


To the Editor, Studies revealed that COVID-19 patients with critical condition demonstrated lower glutathione levels, with a high concentration of reactive species thus showing high ROS/GSH ratio as compared to the patients with mild symptoms. GSH depletion in cells amplifies the viral replication cycle [1], [2] which could be a possible cause of augmented SARS CoV-2 infections in these patients. Histological examination of lung samples from COVID-19 patients showed pulmonary edema and hyaline membrane formation, indicative of acute respiratory distress syndrome (ARDS) [3], [4]. The toxicity of severe lungs injury is supposed to be due to free radicals generation together with deteriorating innate immunity and activation of transcription factors [5]. Experimental and clinical studies confirmed the role of GSH against inflammatory pathologies of the lungs by attenuating Oxidative Stress [6]. This suggests that endogenous glutathione depletion may be a possible consequence of progression of COVID-19 patients from mild to severe illness. Supplementation of glutathione directly is difficult due to its short half life and impermeability to many biological membranes, thus its precursor N-acetyl-cysteine could be used to elevate its intracellular levels. N-acetylcysteine is the promolecule to cysteine, a potent precursor of glutathione, enhancing the intracellular sulphydryl pool as a powerful antioxidant. NAC liquefies mucus by opening disulfide bonds in mucoprotein, reduces viscosity of bronchial and lung secretions and recovers oxygen saturation in the blood. NAC directly inactivates reactive electrolytes and free radicals non-enzymatically and maintains oxidant/ antioxidant balance in cells. At doses more than 1200 mg, it acts as an antioxidant by reducing the formation of pro-inflammatory cytokines, such as IL-9 and TNF-α and also shows vasodilator property by increasing cyclic GMP levels and contributing to the regeneration of endothelial-derived relaxing factor. A placebo controlled study by Zhang et. al., [7] has investigated the antioxidant properties of NAC in exacerbations of chronic obstructive pulmonary disease. NAC also protects against H9N2 swine influenza virus-induced acute lung injury (ALI) thus dictating its therapeutic importance in ALI caused due to influenza virus. Studies also revealed that NAC treatment in ARDS patients can improve the outcome of the patients by rising total thiol molecule and anti-oxidant molecules [8]. This shows the potential benefits of using NAC as therapeutic agent in these patients. There is substantial evidence to support our hypothesis that N-acetyl-cysteine has a potential to be used as a therapeutic agent in the treatment of COVID-19 patients. It is a drug with potency to scavenge Reactive Oxygen Species (ROS), least side effects, and an effective precursor of glutathione. Our hypothesis is worth proving in well designed clinical studies that may benefit in the treatment of COVID-19 patients.

Prior presentation

No data from this manuscript were presented in a scientific forum before.

Funding sources

The article has no funding source

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
  8 in total

Review 1.  GSH and analogs in antiviral therapy.

Authors:  Alessandra Fraternale; Maria Filomena Paoletti; Anna Casabianca; Lucia Nencioni; Enrico Garaci; Anna Teresa Palamara; Mauro Magnani
Journal:  Mol Aspects Med       Date:  2008-09-27

2.  Oral N-acetylcysteine attenuates the rat pulmonary inflammatory response to antigen.

Authors:  S Blesa; J Cortijo; M Mata; A Serrano; D Closa; F Santangelo; J M Estrela; J Suchankova; E J Morcillo
Journal:  Eur Respir J       Date:  2003-03       Impact factor: 16.671

3.  Improvement by N-acetylcysteine of acute respiratory distress syndrome through increasing intracellular glutathione, and extracellular thiol molecules and anti-oxidant power: evidence for underlying toxicological mechanisms.

Authors:  Mohammad Sadegh Soltan-Sharifi; Mojtaba Mojtahedzadeh; Atabak Najafi; Mohammad Reza Khajavi; Mohammad Reza Rouini; Mandana Moradi; Azadeh Mohammadirad; Mohammad Abdollahi
Journal:  Hum Exp Toxicol       Date:  2007-09       Impact factor: 2.903

4.  Influenza virus replication in lung epithelial cells depends on redox-sensitive pathways activated by NOX4-derived ROS.

Authors:  Donatella Amatore; Rossella Sgarbanti; Katia Aquilano; Sara Baldelli; Dolores Limongi; Livia Civitelli; Lucia Nencioni; Enrico Garaci; Maria Rosa Ciriolo; Anna Teresa Palamara
Journal:  Cell Microbiol       Date:  2014-10-07       Impact factor: 3.715

5.  Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury.

Authors:  Yumiko Imai; Keiji Kuba; G Greg Neely; Rubina Yaghubian-Malhami; Thomas Perkmann; Geert van Loo; Maria Ermolaeva; Ruud Veldhuizen; Y H Connie Leung; Hongliang Wang; Haolin Liu; Yang Sun; Manolis Pasparakis; Manfred Kopf; Christin Mech; Sina Bavari; J S Malik Peiris; Arthur S Slutsky; Shizuo Akira; Malin Hultqvist; Rikard Holmdahl; John Nicholls; Chengyu Jiang; Christoph J Binder; Josef M Penninger
Journal:  Cell       Date:  2008-04-18       Impact factor: 41.582

6.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome.

Authors:  Zhe Xu; Lei Shi; Yijin Wang; Jiyuan Zhang; Lei Huang; Chao Zhang; Shuhong Liu; Peng Zhao; Hongxia Liu; Li Zhu; Yanhong Tai; Changqing Bai; Tingting Gao; Jinwen Song; Peng Xia; Jinghui Dong; Jingmin Zhao; Fu-Sheng Wang
Journal:  Lancet Respir Med       Date:  2020-02-18       Impact factor: 30.700

7.  N-acetyl-l-cystine (NAC) protects against H9N2 swine influenza virus-induced acute lung injury.

Authors:  Rui-Hua Zhang; Chun-Hong Li; Cun-Lian Wang; Ming-Ju Xu; Tong Xu; Dong Wei; Bao-Jian Liu; Guo-Hua Wang; Shu-Fei Tian
Journal:  Int Immunopharmacol       Date:  2014-06-24       Impact factor: 4.932

8.  Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer.

Authors:  Sufang Tian; Weidong Hu; Li Niu; Huan Liu; Haibo Xu; Shu-Yuan Xiao
Journal:  J Thorac Oncol       Date:  2020-02-28       Impact factor: 15.609

  8 in total
  6 in total

Review 1.  Multifaceted Roles of Ferroptosis in Lung Diseases.

Authors:  Yi Li; Ying Yang; Yongfeng Yang
Journal:  Front Mol Biosci       Date:  2022-06-24

Review 2.  Use of Thiols in the Treatment of COVID-19: Current Evidence.

Authors:  Mario Cazzola; Paola Rogliani; Sundeep Santosh Salvi; Josuel Ora; Maria Gabriella Matera
Journal:  Lung       Date:  2021-08-27       Impact factor: 2.584

3.  A pilot study on intravenous N-Acetylcysteine treatment in patients with mild-to-moderate COVID19-associated acute respiratory distress syndrome.

Authors:  Abbas Taher; Marjan Lashgari; Ladan Sedighi; Farshid Rahimi-Bashar; Jalal Poorolajal; Maryam Mehrpooya
Journal:  Pharmacol Rep       Date:  2021-06-10       Impact factor: 3.024

Review 4.  N-Acetylcysteine as a treatment for sulphur mustard poisoning.

Authors:  Thomas W Sawyer
Journal:  Free Radic Biol Med       Date:  2020-09-25       Impact factor: 7.376

Review 5.  The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options.

Authors:  Shalki Choudhary; Kajal Sharma; Om Silakari
Journal:  Microb Pathog       Date:  2020-12-02       Impact factor: 3.848

Review 6.  Antioxidants as Therapeutic Agents in Acute Respiratory Distress Syndrome (ARDS) Treatment-From Mice to Men.

Authors:  Andreas von Knethen; Ulrike Heinicke; Volker Laux; Michael J Parnham; Andrea U Steinbicker; Kai Zacharowski
Journal:  Biomedicines       Date:  2022-01-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.